West Pharmaceutical Services news

Strong structural growth drivers from biologics (75% of new drug approvals are large molecules with 90%+ win rates), nearly 800 active Annex 1 projects expected to add 200 basis points of revenue growth, and strong HVP delivery device momentum (29% organic growth). Zacks Rank #2 (Buy) with 16% anticipated earnings improvement over five years and 17.4% trailing four-quarter earnings surprise. However, sentiment is tempered by near-term challenges from West Vantage weakness and commodity inflation.

The company experienced a material cyberattack with data exfiltration and system encryption, causing temporary operational disruption. While management responded swiftly and core systems are being restored, the full financial and operational impact remains undetermined, creating near-term uncertainty for investors. Stock price declined 2.02% on the disclosure.

Company significantly beat Q1 earnings expectations ($2.13 vs $1.68 consensus), delivered 21% revenue growth with strong 15.3% organic growth, and raised full-year 2026 guidance for both revenue ($3.29-$3.35B vs $3.25B estimate) and EPS ($8.40-$8.75 vs $8.01 consensus). GLP-1 business momentum and $1B share buyback authorization further support positive outlook. Stock surged 10.50% on the results.

West Pharmaceutical carries a Zacks Rank #2 (Buy) with strong Q2 2026 results, beating earnings estimates by 13.9% and revenue estimates by 4.2%, with consistent earnings beats and an estimated long-term growth rate of 16%.

Zacks Rank #2 (Buy) with Q2 adjusted EPS of $2.37 beating consensus by 13.9%, revenues beat by 4.2%, consistent earnings beats with 17.4% average surprise, and 16% estimated long-term earnings growth.

Company beat earnings estimates by 13.9% and revenue estimates by 4.2% in Q2 2026, with consistent earnings beats (17.4% average surprise) and estimated long-term earnings growth of 16%.

Zacks Rank #2 with Q2 2026 earnings beat (13.9% above consensus) and 16% estimated long-term earnings growth rate, demonstrating consistent quarterly outperformance.

Zacks Rank #2 (Buy) with strong financial results: Q2 2026 EPS beat estimates by 13.9%, revenues beat by 4.2%. Consistent earnings beats in trailing four quarters with 17.4% average surprise. Long-term earnings growth rate of 16%.

Recommended as a strong medical sector pick with Zacks Rank #2 (Buy). Demonstrated Q2 2026 EPS beat of 13.9% and long-term earnings growth rate of 16%, with consistent quarterly outperformance.

Recommended as a better-ranked alternative with Zacks Rank #2. Reported Q2 2026 adjusted EPS of $2.37, beating estimates by 13.9%, with revenues beating by 4.2%. Shows consistent earnings beats with 17.4% average surprise over trailing four quarters and 16% estimated long-term earnings growth.

Company reported Q2 2026 adjusted EPS of $2.37 beating consensus by 13.9% and revenues of $872.3M beating by 4.2%. Demonstrates strong long-term earnings growth rate of 16% with consistent earnings performance (17.4% average surprise over trailing four quarters).

Carries Zacks Rank #2 (Buy) with solid recent performance, beating Q2 2026 EPS estimates by 13.9% and revenue estimates by 4.2%. Demonstrates consistent earnings beats over trailing four quarters with 17.4% average surprise and 16% estimated long-term earnings growth rate.

Zacks Rank #2 (Buy) rating with Q2 2026 adjusted EPS beat of 13.9% above consensus and revenue beat of 4.2%. Highest long-term earnings growth rate at 16% among peer comparisons and consistent earnings outperformance with 17.4% average surprise.

Strong Q2 2026 results with adjusted EPS beating consensus by 13.9% and revenues beating by 4.2%. Zacks Rank #2 (Buy) with consistent earnings beats over trailing four quarters (average 17.4% surprise) and 16% estimated long-term earnings growth.

Mentioned as a better-ranked alternative stock in the medical space with Zacks Rank #2 (Buy). Strong Q2 2026 earnings performance with 13.9% EPS beat, but not directly related to the main article content.

Faced a cyberattack in May with data exfiltration and encryption, but the article notes it carries a Zacks Rank #2 with strong earnings performance.

Zacks Rank #2 (Buy) with strong 16% long-term earnings growth rate, consistent earnings beats (17.4% average surprise), and solid revenue outperformance.

Zacks Rank #2 (Buy) with strong long-term earnings growth rate of 16%, consistent earnings beats (17.4% average surprise), and solid revenue performance exceeding consensus estimates.

Zacks Rank #2 (Buy) with Q2 2026 EPS of $2.37 beating estimates by 13.9%, consistent earnings beats in trailing four quarters (17.4% average surprise), and 16% estimated long-term earnings growth rate.

Zacks Rank #2 with 16% estimated long-term earnings growth rate, 17.4% average earnings surprise, and 23% year-to-date share gains.

Mentioned as a better-ranked alternative in the medical space with Zacks Rank #2 (Buy), strong Q2 2026 earnings beat (13.9% above consensus), and consistent quarterly outperformance with 16% estimated long-term earnings growth.

Reported Q2 2026 adjusted EPS of $2.37 beating consensus by 13.9%, revenues of $872.3 million beat estimates by 4.2%, carries Zacks Rank #2 (Buy), has 16% estimated long-term earnings growth rate, and beat estimates in all trailing four quarters with 17.4% average surprise.

Newly added to the Gates Foundation portfolio with strong fundamentals: 32 consecutive years of dividend increases, forecasted earnings growth of 14-15% annually through 2027, recession-resistant business model, and potential to achieve Dividend King status within two decades.